Sees FY24 adjusted EBITDA $25M-$30M. Blanchard continued, “We begin 2024 with renewed energy and strong momentum across the new products in our portfolio. Our HA-based Integrity Implant System is receiving very positive feedback, and its full market release is on track for mid-2024. We also remain focused on bringing Hyalofast and Cingal to the U.S. market. As we focus the business on our core strengths and highest value opportunities, we are confident that we will enhance value for shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANIK:
- Anika Reports Fourth Quarter and Year-End 2023 Financial Results
- Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
- Anika Therapeutics Announces Board Chair Transition
- Is ANIK a Buy, Before Earnings?
